Table of Contents
Thrombosis
Volume 2011, Article ID 536062, 16 pages
http://dx.doi.org/10.1155/2011/536062
Review Article

Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Received 12 January 2011; Accepted 17 March 2011

Academic Editor: G. Pineo

Copyright © 2011 Jonathan S. Bleeker and William J. Hogan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Skoda, “Thrombocytosis,” Hematology, pp. 159–167, 2009. View at Google Scholar · View at Scopus
  2. M. Ruggeri, A. Tosetto, M. Frezzato, and F. Rodeghiero, “The Rate of Progression to Polycythemia Vera or Essential Thrombocythemia in Patients with Erythrocytosis or Thrombocytosis,” Annals of Internal Medicine, vol. 139, no. 6, pp. 470–I32, 2003. View at Google Scholar · View at Scopus
  3. C. N. Harrison, D. Bareford, N. Butt et al., “Guideline for investigation and management of adults and children presenting with a thrombocytosis,” British Journal of Haematology, vol. 149, no. 3, pp. 352–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Griesshammer, M. Bangerter, T. Sauer, R. Wennauer, L. Bergmann, and H. Heimpel, “Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count,” Journal of Internal Medicine, vol. 245, no. 3, pp. 295–300, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. C. R. Santhosh-Kumar, M. D. Yohannan, K. E. Higgy, and S. A. Al-Mashhadani, “Thrombocytosis in adults: analysis of 777 patients,” Journal of Internal Medicine, vol. 229, no. 6, pp. 493–495, 1991. View at Google Scholar · View at Scopus
  6. M. D. Yohannan, K. E. Higgy, S. A. Al-Mashhadani, and C. R. Santhosh-Kumar, “Thrombocytosis,” Clinical Pediatrics, vol. 33, no. 6, pp. 340–343, 1994. View at Google Scholar · View at Scopus
  7. D. H. Buss, A. W. Cashell, M. L. O'Connor, F. Richards, and L. D. Case, “Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases,” American Journal of Medicine, vol. 96, no. 3, pp. 247–253, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. C. V. Hutchinson, P. Stelfox, and K. S. Rees-Unwin, “Needle-like cryoglobulin crystals presenting as spurious thrombocytosis,” British Journal of Haematology, vol. 135, no. 3, p. 280, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. S. Ballard and G. Sidhu, “Cytoplasmic fragments causing spurious platelet counts in hairy cell leukemia. Ultrastructural characterization,” Archives of Internal Medicine, vol. 141, no. 7, pp. 942–944, 1981. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Kakkar, “Spurious rise in the automated platelet count because of bacteria,” Journal of Clinical Pathology, vol. 57, no. 10, pp. 1096–1097, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Lawrence and B. Atac, “Hematologic changes in massive burn injury,” Critical Care Medicine, vol. 20, no. 9, pp. 1284–1288, 1992. View at Google Scholar · View at Scopus
  12. K. Kaushansky, “Thrombopoietin: the primary regulator of platelet production,” Blood, vol. 86, no. 2, pp. 419–431, 1995. View at Google Scholar · View at Scopus
  13. K. Kaushansky, “Thrombopoietin and the hematopoietic stem cell,” Blood, vol. 92, no. 1, pp. 1–3, 1998. View at Google Scholar · View at Scopus
  14. M. G. Alexandrakis, F. H. Passam, I. A. Moschandrea et al., “Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis,” American Journal of Clinical Oncology, vol. 26, no. 2, pp. 135–140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Dan, S. Gomi, K. Inokuchi et al., “Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis,” Acta Haematologica, vol. 93, no. 2-4, pp. 67–72, 1995. View at Google Scholar · View at Scopus
  16. H. Hamaguchi, N. Takano, K. Saito, H. Enokihara, S. Furusawa, and H. Shishido, “Interaction of monocytes and T cells in the regulation of normal human megakaryocytopoiesis in vitro: role of IL-1 and IL-2,” British Journal of Haematology, vol. 76, no. 1, pp. 12–20, 1990. View at Google Scholar · View at Scopus
  17. I. C. Haznedaroǧlu, I. Ertenli, O. I. Özcebe et al., “Megakaryocyte-related interleukins in reactive thrombocytosis versus autonomous thrombocythemia,” Acta Haematologica, vol. 95, no. 2, pp. 107–111, 1996. View at Google Scholar · View at Scopus
  18. C. C. Folman, M. Ooms, B. Bart Kuenen et al., “The role of thrombopoietin in post-operative thrombocytosis,” British Journal of Haematology, vol. 114, no. 1, pp. 126–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Tefferi, T. C. Ho, G. J. Ahmann, J. A. Katzmann, and P. R. Greipp, “Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis,” American Journal of Medicine, vol. 97, no. 4, pp. 374–377, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. C. W. Hollen, J. Henthorn, J. A. Koziol, and S. A. Burstein, “Elevated serum interleukin-6 levels in patients with reactive thrombocytosis,” British Journal of Haematology, vol. 79, no. 2, pp. 286–290, 1991. View at Google Scholar · View at Scopus
  21. A. Ishiguro, Y. Suzuki, M. Mito et al., “Elevation of serum thrombopoietin precedes thrombocytosis in acute infections,” British Journal of Haematology, vol. 116, no. 3, pp. 612–618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. H. C. Hsu, W. H. Tsai, M. L. Jiang et al., “Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis,” Journal of Laboratory and Clinical Medicine, vol. 134, no. 4, pp. 392–397, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Wendling and Z. C. Han, “Positive and negative regulation of megakaryocytopoiesis,” Bailliere's Clinical Haematology, vol. 10, no. 1, pp. 29–45, 1997. View at Google Scholar · View at Scopus
  24. I. Ertenli, S. Kiraz, M. A. Öztürk, I. C. Haznedaroǧlu, I. Çelik, and M. Çalgüneri, “Pathologic thrombopoiesis of rheumatoid arthritis,” Rheumatology International, vol. 23, no. 2, pp. 49–60, 2003. View at Google Scholar · View at Scopus
  25. F. Heits, M. Stahl, D. Ludwig, E. F. Stange, and W. Jelkmann, “Elevated serum thrombopoietin and interleukin-6 concentrations in thrombocytosis associated with inflammatory bowel disease,” Journal of Interferon and Cytokine Research, vol. 19, no. 7, pp. 757–760, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Uppenkamp, E. Makarova, S. Petrasch, and G. Brittinger, “Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis,” Annals of Hematology, vol. 77, no. 5, pp. 217–223, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Cerutti, P. Custodi, M. Duranti, P. Noris, and C. L. Balduini, “Thrombopoietin levels in patients with primary and reactive thrombocytosis,” British Journal of Haematology, vol. 99, no. 2, pp. 281–284, 1997. View at Google Scholar · View at Scopus
  28. M. Hou, J. Carneskog, U. H. Mellqvist et al., “Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis,” European Journal of Haematology, vol. 61, no. 2, pp. 119–122, 1998. View at Google Scholar · View at Scopus
  29. J. C. Osselaer, J. Jamart, and J. M. Scheiff, “Platelet distribution width for differential diagnosis of thrombocytosis,” Clinical Chemistry, vol. 43, no. 6, pp. 1072–1076, 1997. View at Google Scholar · View at Scopus
  30. A. E. Tsantes, A. Dimoula, S. Bonovas et al., “The role of the Platelet Function Analyzer (PFA)-100 and platelet aggregometry in the differentiation of essential thrombocythemia from reactive thrombocytosis,” Thrombosis Research, vol. 125, no. 2, pp. 142–146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. D. V. Gnatenko, W. Zhu, X. Xu et al., “Class prediction models of thrombocytosis using genetic biomarkers,” Blood, vol. 115, no. 1, pp. 7–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Kuku, E. Kaya, S. Yologlu, R. Gokdeniz, and A. Baydin, “Platelet counts in adults with iron deficiency anemia,” Platelets, vol. 20, no. 6, pp. 401–405, 2009. View at Google Scholar · View at Scopus
  33. H. Akan, N. Giiven, I. Aydogdu, M. Arat, M. Beksac, and K. Dalva, “Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis,” Acta Haematologica, vol. 103, no. 3, pp. 152–156, 2000. View at Google Scholar · View at Scopus
  34. P. J. Stohlawetz, L. Dzirlo, N. Hergovich et al., “Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans,” Blood, vol. 95, no. 9, pp. 2983–2989, 2000. View at Google Scholar · View at Scopus
  35. C. J. Kaupke, G. C. Butler, and N. D. Vaziri, “Effect of recombinant human erythropoietin on platelet production in dialysis patients,” Journal of the American Society of Nephrology, vol. 3, no. 10, pp. 1672–1679, 1993. View at Google Scholar · View at Scopus
  36. E. Streja, C. P. Kovesdy, S. Greenland et al., “Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis,” American Journal of Kidney Diseases, vol. 52, no. 4, pp. 727–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Bilic and E. Bilic, “Amino acid sequence homology of thrombopoietin and erythropoietin may explain thrombocytosis in children with iron deficiency anemia,” Journal of Pediatric Hematology, vol. 25, no. 8, pp. 675–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. V. C. Broudy, N. L. Lin, D. F. Sabath, T. Papayannopoulou, and K. Kaushansky, “Human platelets display high-affinity receptors for thrombopoietin,” Blood, vol. 89, no. 6, pp. 1896–1904, 1997. View at Google Scholar · View at Scopus
  39. V. C. Broudy, N. L. Lin, and K. Kaushansky, “Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro,” Blood, vol. 85, no. 7, pp. 1719–1726, 1995. View at Google Scholar · View at Scopus
  40. O. S. Balçik, M. Öztürk, M. Daǧli et al., “Increased erythropoietin levels in reactive thrombocytosis,” Haematologia, vol. 32, no. 1, pp. 59–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Tefferi, J. Thiele, and J. W. Vardiman, “The 2008 world health organization classification system for myeloproliferative neoplasms: order out of chaos,” Cancer, vol. 115, no. 17, pp. 3842–3847, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. H. Swerdlow et al., WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, WHO, 4th edition, 2008.
  43. C. R. Bartram, A. De Klein, and A. Hagemeijer, “Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia,” Nature, vol. 306, no. 5940, pp. 277–280, 1983. View at Google Scholar · View at Scopus
  44. D. G. Savage, R. M. Szydlo, and J. M. Goldman, “Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period,” British Journal of Haematology, vol. 96, no. 1, pp. 111–116, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. E. J. Baxter, L. M. Scott, P. J. Campbell et al., “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders,” Lancet, vol. 365, no. 9464, pp. 1054–1061, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. C. James, V. Ugo, J. P. Le Couédic et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera,” Nature, vol. 434, no. 7037, pp. 1144–1148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Kralovics, F. Passamonti, A. S. Buser et al., “A gain-of-function mutation of JAK2 in myeloproliferative disorders,” New England Journal of Medicine, vol. 352, no. 17, pp. 1779–1790, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. R. L. Levine, M. Wadleigh, J. Cools et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis,” Cancer Cell, vol. 7, no. 4, pp. 387–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Zhao, S. Xing, Z. Li et al., “Identification of an acquired JAK2 mutation in polycythemia vera,” Journal of Biological Chemistry, vol. 280, no. 24, pp. 22788–22792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Parganas, D. Wang, D. Stravopodis et al., “Jak2 is essential for signaling through a variety of cytokine receptors,” Cell, vol. 93, no. 3, pp. 385–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. N. Radosevic, D. Winterstein, J. R. Keller, H. Neubauer, K. Pfeffer, and D. Linnekin, “JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor,” Experimental Hematology, vol. 32, no. 2, pp. 149–156, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Ugo, C. Marzac, I. Teyssandier et al., “Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera,” Experimental Hematology, vol. 32, no. 2, pp. 179–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. P. S. Goerttler, C. Steimle, E. März et al., “The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients,” Blood, vol. 106, no. 8, pp. 2862–2864, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. A. A. Axelrad, D. Eskinazi, P. N. Correa, and D. Amato, “Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia,” Blood, vol. 96, no. 10, pp. 3310–3321, 2000. View at Google Scholar · View at Scopus
  55. E. Lippert, M. Boissinot, R. Kralovics et al., “The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera,” Blood, vol. 108, no. 6, pp. 1865–1867, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Saharinen, K. Takaluoma, and O. Silvennoinen, “Regulation of the Jak2 tyrosine kinase by its pseudokinase domain,” Molecular and Cellular Biology, vol. 20, no. 10, pp. 3387–3395, 2000. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Saharinen, M. Vihinen, and O. Silvennoinen, “Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain,” Molecular Biology of the Cell, vol. 14, no. 4, pp. 1448–1459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. X. Lu, R. Levine, W. Tong et al., “Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 52, pp. 18962–18967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. S. N. Constantinescu, T. Keren, M. Socolovsky, H. S. Nam, Y. I. Henis, and H. F. Lodish, “Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 8, pp. 4379–4384, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. W. S. Alexander, A. W. Roberts, A. B. Maurer, N. A. Nicola, A. R. Dunn, and D. Metcalf, “Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation,” Stem Cells, vol. 14, no. 1, pp. 124–132, 1996. View at Google Scholar · View at Scopus
  61. L. F. Grimwade, L. Happerfield, C. Tristram et al., “Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms,” British Journal of Haematology, vol. 147, no. 4, pp. 495–506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Kittur, R. A. Knudson, T. L. Lasho et al., “Clinical correlates of JAK2V617F allele burden in essential thrombocythemia,” Cancer, vol. 109, no. 11, pp. 2279–2284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Antonioli, P. Guglielmelli, G. Poli et al., “Influence of JAK2 allele burden on phenotype in essential thrombocythemia,” Haematologica, vol. 93, no. 1, pp. 41–48, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Passamonti, E. Rumi, D. Pietra et al., “Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 cells into peripheral blood in myeloproliferative disorders,” Blood, vol. 107, no. 9, pp. 3676–3682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Passamonti and E. Rumi, “Clinical relevance of JAK2 (V617F) mutant allele burden,” Haematologica, vol. 94, no. 1, pp. 7–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. A. M. Vannucchi, E. Antonioli, P. Guglielmelli et al., “Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia,” Blood, vol. 110, no. 3, pp. 840–846, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Jelinek, Y. Oki, V. Gharibyan et al., “JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia,” Blood, vol. 106, no. 10, pp. 3370–3373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. D. P. Steensma, G. W. Dewald, T. L. Lasho et al., “The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes,” Blood, vol. 106, no. 4, pp. 1207–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Kralovics, S. S. Teo, S. Li et al., “Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders,” Blood, vol. 108, no. 4, pp. 1377–1380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. J. R. Lambert, T. Everington, D. C. Linch, and R. E. Gale, “In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm,” Blood, vol. 114, no. 14, pp. 3018–3023, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Rumi, F. Passamonti, D. Pietra et al., “JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders,” Cancer, vol. 107, no. 9, pp. 2206–2211, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Pietra, S. Li, A. Brisci et al., “Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders,” Blood, vol. 111, no. 3, pp. 1686–1689, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Schnittger, U. Bacher, C. Haferlach et al., “Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera,” Haematologica, vol. 94, no. 3, pp. 414–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. L. M. Scott, W. Tong, R. L. Levine et al., “JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis,” New England Journal of Medicine, vol. 356, no. 5, pp. 459–468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Albiero, D. Madeo, M. Ruggeri, M. Bernardi, A. Giorgetti, and F. Rodeghiero, “Loss of the JAK2 intramolecular auto-inhibition mechanism is predicted by structural modelling of a novel exon 12 insertion mutation in a case of idiopathic erythrocytosis,” British Journal of Haematology, vol. 142, no. 6, pp. 986–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. J. Staerk, C. Lacout, T. Sato, S. O. Smith, W. Vainchenker, and S. N. Constantinescu, “An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor,” Blood, vol. 107, no. 5, pp. 1864–1871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Pikman, B. H. Lee, T. Mercher et al., “MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia,” PLoS Medicine, vol. 3, no. 7, article e270, pp. 1140–1151, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. P. A. Beer, P. J. Campbell, L. M. Scott et al., “MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort,” Blood, vol. 112, no. 1, pp. 141–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. A. D. Pardanani, R. L. Levine, T. Lasho et al., “MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients,” Blood, vol. 108, no. 10, pp. 3472–3476, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. A. M. Vannucchi, E. Antonioli, P. Guglielmelli et al., “Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia,” Blood, vol. 112, no. 3, pp. 844–847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Delhommeau, S. Dupont, V. Della Valle et al., “Mutation in TET2 in myeloid cancers,” New England Journal of Medicine, vol. 360, no. 22, pp. 2289–2301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Tefferi et al., “TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis,” Leukemia, vol. 23, no. 5, pp. 905–911, 2009. View at Google Scholar
  83. F. X. Schaub, R. Looser, S. Li et al., “Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms,” Blood, vol. 115, no. 10, pp. 2003–2007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. E. M. Boyd, A. J. Bench, A. Goday-Fernández et al., “Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis: research paper,” British Journal of Haematology, vol. 149, no. 2, pp. 250–257, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. J. W. Vardiman, J. Thiele, D. A. Arber et al., “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes,” Blood, vol. 114, no. 5, pp. 937–951, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. N. I. Berlin, “Diagnosis and classification of the polycythemias,” Seminars in Hematology, vol. 12, no. 4, pp. 339–351, 1975. View at Google Scholar · View at Scopus
  87. P. A. Beer and A. R. Green, “Pathogenesis and management of essential thrombocythemia,” Hematology, vol. 2009, no. 1, pp. 621–628, 2009. View at Google Scholar · View at Scopus
  88. J. L. Spivak, “Polycythemia vera: myths, mechanisms, and management,” Blood, vol. 100, no. 13, pp. 4272–4290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Shaw and G. R. Tudhope, “Thrombocytosis, thrombocythaemia and iron deficiency in patients with polycythaemia vera,” Acta Haematologica, vol. 62, no. 4, pp. 223–228, 1979. View at Google Scholar · View at Scopus
  90. B. Dupriez, P. Morel, J. L. Demory et al., “Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system,” Blood, vol. 88, no. 3, pp. 1013–1018, 1996. View at Google Scholar · View at Scopus
  91. D. H. Buss, J. J. Stuart, and G. E. Lipscomb, “The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases,” American Journal of Hematology, vol. 20, no. 4, pp. 365–372, 1985. View at Google Scholar · View at Scopus
  92. W. W. Coon, J. Penner, G. P. Clagett, and N. Eos, “Deep venous thrombosis and postsplenectomy thrombocytosis,” Archives of Surgery, vol. 113, no. 4, pp. 429–431, 1978. View at Google Scholar · View at Scopus
  93. J. L. Kashuk et al., “Progressive postinjury thrombocytosis is associated with thromboembolic complications,” Surgery, vol. 148, no. 4, pp. 667–675, 2010. View at Google Scholar
  94. M. Schmuziger et al., “Reactive thrombocytosis after coronary bypass surgery: an important risk factor,” European Journal of Cardiothoracic Surgery, vol. 9, pp. 393–397, 1995. View at Google Scholar
  95. J. J. Michiels, J. Abels, and J. Steketee, “Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia,” Annals of Internal Medicine, vol. 102, no. 4, pp. 466–471, 1985. View at Google Scholar · View at Scopus
  96. P. J. J. Van Genderen and J. J. Michiels, “Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera,” Seminars in Thrombosis and Hemostasis, vol. 23, no. 4, pp. 357–363, 1997. View at Google Scholar · View at Scopus
  97. A. Tefferi, R. Fonseca, D. L. Pereira, and H. Clark Hoagland, “A long-term retrospective study of young women with essential thrombocythemia,” Mayo Clinic Proceedings, vol. 76, no. 1, pp. 22–28, 2001. View at Google Scholar · View at Scopus
  98. A. Chistolini, M. Gabriella Muzzucconi, A. Ferrari et al., “Essential thrombocythemia: a retrospective study on the clinical course of 100 patients,” Haematologica, vol. 75, no. 6, pp. 537–540, 1990. View at Google Scholar · View at Scopus
  99. P. Fenaux, M. Simon, M. T. Caulier, J. L. Lai, J. Goudemand, and F. Bauters, “Clinical course of essential thrombocythemia in 147 cases,” Cancer, vol. 66, no. 3, pp. 549–556, 1990. View at Publisher · View at Google Scholar · View at Scopus
  100. P. J. J. Van Genderen, F. J. Prins, J. J. Michiels, and K. Schrör, “Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent,” British Journal of Haematology, vol. 104, no. 3, pp. 438–441, 1999. View at Google Scholar · View at Scopus
  101. J. S. Cohen, “Erythromelalgia: new theories and new therapies,” Journal of the American Academy of Dermatology, vol. 43, no. 5, pp. 841–847, 2000. View at Google Scholar · View at Scopus
  102. R. Marchioli, G. Finazzi, R. Landolfi et al., “Vascular and neoplastic risk in a large cohort of patients with polycythemia vera,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2224–2232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. M. A. Elliott and A. Tefferi, “Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia,” British Journal of Haematology, vol. 128, no. 3, pp. 275–290, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Landolfi, L. Di Gennaro, and A. Falanga, “Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation,” Leukemia, vol. 22, no. 11, pp. 2020–2028, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. Gruppo Italiano Studio Policitemia, “Polycythemia vera: the natural history of 1213 patients followed for 20 years,” Annals of Internal Medicine, vol. 123, pp. 656–664, 1995. View at Google Scholar
  106. A. P. Wolanskyj, S. M. Schwager, R. F. McClure, D. R. Larson, and A. Tefferi, “Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors,” Mayo Clinic Proceedings, vol. 81, no. 2, pp. 159–166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Besses, F. Cervantes, A. Pereira et al., “Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients,” Leukemia, vol. 13, no. 2, pp. 150–154, 1999. View at Google Scholar · View at Scopus
  108. M. Colombi, F. Radaelli, L. Zocchi, and A. T. Maiolo, “Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients,” Cancer, vol. 67, no. 11, pp. 2926–2930, 1991. View at Google Scholar · View at Scopus
  109. N. Gangat, J. Strand, C. Y. Li, W. Wu, A. Pardanani, and A. Tefferi, “Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation,” British Journal of Haematology, vol. 138, no. 3, pp. 354–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Lengfelder et al., “Should a platelet limit of 600×109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages,” British Journal of Haematology, vol. 100, no. 1, pp. 15–23, 1998. View at Google Scholar
  111. M. Bazzan, G. Tamponi, P. Schinco et al., “Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia,” Annals of Hematology, vol. 78, no. 12, pp. 539–543, 1999. View at Google Scholar · View at Scopus
  112. G. Perea, A. Remacha, C. Besses, M. Jiménez, L. Florensa, and F. Cervantes, “Is polycythemia vera a serious disease in young adults?” Haematologica, vol. 86, no. 5, pp. 543–544, 2001. View at Google Scholar · View at Scopus
  113. Y. Chait et al., “Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis,” British Journal of Haematology, vol. 129, no. 4, pp. 553–560, 2005. View at Google Scholar
  114. J. B. Brière, “Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management,” Seminars in Thrombosis and Hemostasis, vol. 32, no. 3, pp. 208–218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. R. K. Patel, N. C. Lea, M. A. Heneghan et al., “Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome,” Gastroenterology, vol. 130, no. 7, pp. 2031–2038, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Primignani, G. Barosi, G. Bergamaschi et al., “Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis,” Hepatology, vol. 44, no. 6, pp. 1528–1534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. A. W. Tsai, M. Cushman, W. D. Rosamond, S. R. Heckbert, J. F. Polak, and A. R. Folsom, “Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology,” Archives of Internal Medicine, vol. 162, no. 10, pp. 1182–1189, 2002. View at Google Scholar · View at Scopus
  118. A. Carobbio, E. Antonioli, P. Guglielmelli et al., “Leukocytosis and risk stratification assessment in essential thrombocythemia,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2732–2736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Landolfi, L. Di Gennaro, T. Barbui et al., “Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera,” Blood, vol. 109, no. 6, pp. 2446–2452, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Tefferi, N. Gangat, and A. Wolanskyj, “The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia,” Blood, vol. 109, no. 9, p. 4105, 2007. View at Google Scholar
  121. A. Wehmeier, I. Daum, H. Jamin, and W. Schneider, “Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients,” Annals of Hematology, vol. 63, no. 2, pp. 101–106, 1991. View at Google Scholar · View at Scopus
  122. A. Falanga, M. Marchetti, V. Evangelista et al., “Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera,” Blood, vol. 96, no. 13, pp. 4261–4266, 2000. View at Google Scholar · View at Scopus
  123. G. Barosi, G. Birgegard, G. Finazzi et al., “Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference,” Blood, vol. 113, no. 20, pp. 4829–4833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. M. K. Jensen, P. De Nully Brown, O. J. Nielsen, and H. C. Hasselbalch, “Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area,” European Journal of Haematology, vol. 65, no. 2, pp. 132–139, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Regev, P. Stark, D. Blickstein, and M. Lahav, “Thrombotic complications in essential thrombocythemia with relatively low platelet counts,” American Journal of Hematology, vol. 56, no. 3, pp. 168–172, 1997. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Cortelazzo, G. Finazzi, M. Ruggeri et al., “Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis,” New England Journal of Medicine, vol. 332, no. 17, pp. 1132–1136, 1995. View at Publisher · View at Google Scholar · View at Scopus
  127. R. Landolfi, B. Rocca, and C. Patrono, “Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment,” Critical Reviews in Oncology/Hematology, vol. 20, no. 3, pp. 203–222, 1995. View at Publisher · View at Google Scholar · View at Scopus
  128. M. K. Jensen, P. De Nully Brown, B. V. Lund, O. J. Nielsen, and H. C. Hasselbalch, “Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders,” British Journal of Haematology, vol. 110, no. 1, pp. 116–124, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. R. Landolfi et al., “Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo,” Blood, vol. 80, no. 8, pp. 1965–1971, 1992. View at Google Scholar
  130. T. C. Pearson and G. Wetherley-Mein, “Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia,” Lancet, vol. 2, no. 8102, pp. 1219–1222, 1978. View at Google Scholar · View at Scopus
  131. H. C. Kwaan and J. Wang, “Hyperviscosity in polycythemia vera and other red cell abnormalities,” Seminars in Thrombosis and Hemostasis, vol. 29, no. 5, pp. 451–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  132. P. Y. Huang and J. D. Hellums, “Aggregation and disaggregation kinetics of human blood platelets—part III. The disaggregation under shear stress of platelet aggregates,” Biophysical Journal, vol. 65, no. 1, pp. 354–361, 1993. View at Google Scholar
  133. M.-P. Wautier et al., “Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin {alpha}5 chain and Lu/BCAM,” Blood, vol. 110, no. 3, pp. 894–901, 2007. View at Google Scholar
  134. J. Shibata, J. Hasegawa, H. J. Siemens et al., “Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis,” Blood, vol. 101, no. 11, pp. 4416–4422, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. R. Jantunen, E. Juvonen, E. Ikkala, K. Oksanen, P. Anttila, and T. Ruutu, “The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia,” Annals of Hematology, vol. 80, no. 2, pp. 74–78, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. B. Cheung, D. Radia, P. Pantelidis, G. Yadegarfar, and C. Harrison, “The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia,” British Journal of Haematology, vol. 132, no. 2, pp. 244–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  137. R. S. M. Wong, C. K. Cheng, N. P. H. Chan et al., “JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia,” British Journal of Haematology, vol. 141, no. 6, pp. 902–904, 2008. View at Publisher · View at Google Scholar · View at Scopus
  138. P. J. Campbell, L. M. Scott, G. Buck et al., “Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study,” Lancet, vol. 366, no. 9501, pp. 1945–1953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  139. A. P. Wolanskyj, T. L. Lasho, S. M. Schwager et al., “JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance,” British Journal of Haematology, vol. 131, no. 2, pp. 208–213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  140. F. Lussana, S. Caberlon, C. Pagani, P. W. Kamphuisen, H. R. Büller, and M. Cattaneo, “Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review,” Thrombosis Research, vol. 124, no. 4, pp. 409–417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. U. Budde, R. E. Scharf, P. Franke, K. Hartmann-Budde, J. Dent, and Z. M. Ruggeri, “Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma,” Blood, vol. 82, no. 6, pp. 1749–1757, 1993. View at Google Scholar · View at Scopus
  142. P. J. J. Van Genderen, U. Budde, J. J. Michiels, R. Van Strik, and H. H. D. M. Van Vliet, “The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count,” British Journal of Haematology, vol. 93, no. 4, pp. 962–965, 1996. View at Google Scholar · View at Scopus
  143. B. Thakral, K. Saluja, P. Malhotra, R. R. Sharma, N. Marwaha, and S. Varma, “Therapeutic plateletpheresis in a case of symptomatic thrombocytosis in chronic myeloid leukemia,” Therapeutic Apheresis and Dialysis, vol. 8, no. 6, pp. 497–499, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. E. G. Taft, R. B. Babcock, W. B. Scharfman, and A. P. Tartaglia, “Plateletpheresis in the management of thrombocytosis,” Blood, vol. 50, no. 5, pp. 927–933, 1977. View at Google Scholar · View at Scopus
  145. B. W. Baron, R. Mick, and J. M. Baron, “Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders,” Cancer, vol. 72, no. 4, pp. 1209–1218, 1993. View at Google Scholar · View at Scopus
  146. C. N. Harrison, P. J. Campbell, G. Buck et al., “Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia,” New England Journal of Medicine, vol. 353, no. 1, pp. 33–45, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Tomer, “Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia,” Blood, vol. 99, no. 5, pp. 1602–1609, 2002. View at Publisher · View at Google Scholar · View at Scopus
  148. M. D'adda, M. Micheletti, M. Drera, S. Ferrari, and G. Rossi, “The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy,” Leukemia and Lymphoma, vol. 49, no. 11, pp. 2216–2218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. M. Ruggeri, G. Finazzi, A. Tosetto, S. Riva, F. Rodeghiero, and T. Barbui, “No treatment for low-risk thrombocythaemia: results from a prospective study,” British Journal of Haematology, vol. 103, no. 3, pp. 772–777, 1998. View at Publisher · View at Google Scholar · View at Scopus
  150. P. J. J. Van Genderen, P. G. H. Mulder, M. Waleboer, D. Van De Moesdijk, and J. J. Michiels, “Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin,” British Journal of Haematology, vol. 97, no. 1, pp. 179–184, 1997. View at Google Scholar · View at Scopus
  151. R. Landolfi, R. Marchioli, J. Kutti et al., “Efficacy and safety of low-dose aspirin in polycythemia vera,” New England Journal of Medicine, vol. 350, no. 2, pp. 114–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  152. A. Alvarez-Larran et al., “Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia,” Blood, vol. 116, no. 8, pp. 1205–1210, 2010. View at Google Scholar
  153. P. D. Berk, J. D. Goldberg, and M. N. Silverstein, “Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy,” New England Journal of Medicine, vol. 304, no. 8, pp. 441–447, 1981. View at Google Scholar · View at Scopus
  154. P. D. Berk, J. D. Goldberg, P. B. Donovan, S. M. Fruchtman, N. I. Berlin, and L. R. Wasserman, “Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols,” Seminars in hematology, vol. 23, no. 2, pp. 132–143, 1986. View at Google Scholar · View at Scopus
  155. S. M. Fruchtman, K. Mack, M. E. Kaplan, P. Peterson, P. D. Berk, and L. R. Wasserman, “From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera,” Seminars in Hematology, vol. 34, no. 1, pp. 17–23, 1997. View at Google Scholar · View at Scopus
  156. N. I. Berlin, “Polycythemia vera,” Hematology/Oncology Clinics of North America, vol. 17, no. 5, pp. 1191–1210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  157. S. Lanzkron, J. J. Strouse, R. Wilson et al., “Systematic review: hydroxyurea for the treatment of adults with sickle cell disease,” Annals of Internal Medicine, vol. 148, no. 12, pp. 939–955, 2008. View at Google Scholar · View at Scopus
  158. I. Nielsen and H. C. Hasselbalch, “Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan,” American Journal of Hematology, vol. 74, no. 1, pp. 26–31, 2003. View at Google Scholar
  159. G. Finazzi and T. Barbui, “How I treat patients with polycythemia vera,” Blood, vol. 109, no. 12, pp. 5104–5111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. A. P. Tartaglia, J. D. Goldberg, P. D. Berk, and L. R. Wasserman, “Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera,” Seminars in Hematology, vol. 23, no. 3, pp. 172–176, 1986. View at Google Scholar · View at Scopus
  161. Grupo Italiano Studio Policitemia, “Low-dose aspirin in polycythaemia vera: a pilot study,” British Journal of Haematology, vol. 97, no. 2, pp. 453–456, 1997. View at Google Scholar
  162. A. Quintás-Cardama, H. Kantarjian, T. Manshouri et al., “Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5418–5424, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. J. J. Kiladjian, B. Cassinat, S. Chevret et al., “Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera,” Blood, vol. 112, no. 8, pp. 3065–3072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  164. F. Passamonti, L. Malabarba, E. Orlandi et al., “Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis,” British Journal of Haematology, vol. 116, no. 4, pp. 855–861, 2002. View at Publisher · View at Google Scholar · View at Scopus
  165. Y. Najean and J. D. Rain, “Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years,” Blood, vol. 90, no. 9, pp. 3370–3377, 1997. View at Google Scholar · View at Scopus
  166. C. Harrison, “Pregnancy and its management in the Philadelphia negative myeloproliferative diseases,” British Journal of Haematology, vol. 129, no. 3, pp. 293–306, 2005. View at Publisher · View at Google Scholar · View at Scopus
  167. S. Verstovsek, “Therapeutic potential of JAK2 inhibitors,” Hematology, pp. 636–642, 2009. View at Google Scholar · View at Scopus
  168. A. T. Chen and J. T. Prchal, “JAK2 kinase inhibitors and myeloproliferative disorders,” Current Opinion in Hematology, vol. 17, no. 2, pp. 110–116, 2010. View at Publisher · View at Google Scholar · View at Scopus